PURPOSE: A manufacturing method of a (S)-metoprolol is provided to obtain highly pre target materials with high yield under a mild reaction condition by using low-priced starting materials. CONSTITUTION: A manufacturing method of a (S)-metoprolol comprises a step of manufacturing (R)-1-[4-(2-methoxyethyl)phenoxy]-3-chloro-2-propanol by the reaction between (R)-epichlorohydrin and 4-(2-methoxyethyl)phenol under the presence of a chiral salen catalyst

The present invention relates to a method for manufacturing (S)-metoprolol which is used as a depressant, and more specifically, to a novel method for effectively manufacturing high purity (S)-metoprolol, comprising the steps of: carrying out a condensation reaction of (R)-epichlorohydrin and 4-(2-methoxyethyl) phenol, which are starting materials, by using a chiral salen catalyst under a very mild condition in which racemization is suppressed

This invention relates to the use of pharmaceutical compositions comprising a therapeutically effective combination of Tesofensine and Metoprolol for preventing the cardiovascular side effects of Tesofensine, while leaving the robust inhibitory efficacy on food intake and body weight loss unaffected.

The present invention relates to a once-a-day therapeutically synergistic pharmaceutical dosage form for treatment of cardiovascular disorders, wherein the dosage form comprises a fixed dose combination of metoprolol in extended release form and one or more antiplatelet agent along with one or more rate controlling excipients.